Year 2006 update of the Israel National List of Health Services

Israel Medical Association Journal

Volumn 8, Issue 9, 2006, Pages 595-600

  Tamir, Orly ^a   Rabinovich, Mordechai ^b,c   Shani, Mordechai ^a,d  

^a GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^b MACCABI HEALTHCARE SERVICES   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Health services; Medical advances; Priority setting; Public funding; Resource allocation

Indexed keywords

ADEFOVIR DIPIVOXIL; AGALSIDASE ALFA; BORTEZOMIB; CANDESARTAN HEXETIL; CAPECITABINE; CETUXIMAB; CLOPIDOGREL; DEFERASIROX; ETIRACETAM; EZETIMIBE; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; LETROZOLE; LOSARTAN; OCSAAR; OLANZAPINE; OMALIZUMAB; OXALIPLATIN; QUETIAPINE; RITUXIMAB; ROSUVASTATIN; TENOFOVIR; TETRABENAZINE; TOBRAMYCIN; TRASTUZUMAB; UNINDEXED DRUG; VALSARTAN; ZOLEDRONIC ACID; ZOMERA;

ALLERGIC ASTHMA; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BIPOLAR DISORDER; BREAST CANCER; BUDGET; CANCER ADJUVANT THERAPY; COLON CANCER; CONGESTIVE HEART FAILURE; CYSTIC FIBROSIS; DIABETES MELLITUS; FABRY DISEASE; FUNDING; GOVERNMENT REGULATION; HEAD AND NECK CANCER; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH CARE NEED; HEALTH SERVICE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IRON OVERLOAD; ISRAEL; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; MOTOR DYSFUNCTION; MULTIPLE MYELOMA; NATIONAL HEALTH SERVICE; NONHODGKIN LYMPHOMA; PROSTATE CANCER; PUBLIC HEALTH; RESOURCE ALLOCATION; SQUAMOUS CELL CARCINOMA; STROKE;

BIOMEDICAL TECHNOLOGY; BUDGETS; DECISION MAKING, ORGANIZATIONAL; HEALTH CARE COSTS; HEALTH PRIORITIES; HUMANS; ISRAEL; NATIONAL HEALTH PROGRAMS; RESOURCE ALLOCATION; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 33749062781     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Shani S, Siebzehner MI, Luxenburg O, Shemer J. Setting priorities for the adoption of health technologies on a national level - the Israeli experience. Health Policy 2000;54(3):169-85.
2. Shemer J, Morginstin T, Hammerman A, et al. Promoting medical technologies in the national list of health services: 1995-2000. Harefuah 2003;142(2):82-6 (Hebrew).
3. Shani S, Yahalom Z. The Israeli model for managing the National List of Health Services in an era of limited resources. Law Policy 2002;24(2):133-47.
4. Economic Arrangements Law of 2006. Available at: www.mof.gov.il/ budget2006/mainpagin.htm
5. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659-72.
7. Mohr PE, Mueller C, Neumann P, et al. The impact of medical technology on future health care costs. Bethesda, MD: Project HOPE, 2001.
8. Wanless D. Securing our Future Health: Taking a Long-Term View. London: HM Treasury, 2002.
9. Productivity Commission. Impact of advances in medical technology in Australia - Research report. Commonwealth of Australia, Melbourne AU, 2005.